Drug & intervention
irinotecan hydrochloride
RxCUI 153329
Understanding this RxNorm record
RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.
Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.
Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
irinotecan hydrochloride
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownTesting the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerNCT04514497 · 2021-10-20
ACTIVE_NOT_RECRUITINGM6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02595931 · 2016-07-22
ACTIVE_NOT_RECRUITINGPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26
TERMINATEDAzacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT01935947 · 2013-05-01
TERMINATEDA Pilot Study of Irinotecan in Patients With Breast Cancer and CNS MetastasesNCT01939483 · 2012-12-01
WITHDRAWNSunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by SurgeryNCT00936832 · 2009-04-01
WITHDRAWNVeliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryNCT00576654 · 2008-03-18
COMPLETEDFeasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung CancerNCT00546130 · 2007-11-01
UNKNOWNCetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or LungNCT00557102 · 2007-09-01
COMPLETEDIrinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast CancerNCT00693719 · 2007-08-01
COMPLETEDCombination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT00616785 · 2007-06-01
UNKNOWNCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by SurgeryNCT00513266 · 2007-06-01
UNKNOWNIrinotecan and Cetuximab in Treating Patients With Metastatic Breast CancerNCT00275041 · 2006-02-01
COMPLETEDIrinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain MetastasesNCT00617539 · 2005-02-01
COMPLETEDCisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerNCT00118235 · 2004-12-01
COMPLETEDIrinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung CancerNCT00182806 · 2004-09-01
COMPLETEDAmrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung CancerNCT00132054 · 2004-05-01
COMPLETEDTrastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast CancerNCT00303992 · 2004-05-01
COMPLETEDIrinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast CancerNCT00079118 · 2004-04-01
COMPLETEDCarboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung CancerNCT00449020 · 2004-01-01
COMPLETEDIrinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00469898 · 2003-12-01
COMPLETEDCisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00072527 · 2003-11-01
COMPLETEDCombination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00073866 · 2003-06-01
COMPLETEDIrinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung CancerNCT00104793 · 2003-06-01
COMPLETEDCombination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00052494 · 2003-04-01
COMPLETEDChemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00059761 · 2003-03-01
COMPLETEDNeoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00062322 · 2003-02-01
COMPLETEDS0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung CancerNCT00045162 · 2002-11-01
COMPLETEDIrinotecan and Capecitabine in Treating Women With Advanced Breast CancerNCT00083148 · 2002-11-01
COMPLETEDUCN-01 and Irinotecan in Treating Patients With Advanced Solid TumorsNCT00047242 · 2002-08-01
COMPLETEDImatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00045604 · 2002-07-01
COMPLETEDS0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00030433 · 2002-01-01
COMPLETED7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01
COMPLETEDCombination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00025285 · 2001-11-01
COMPLETEDCombination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung CancerNCT00005972 · 2000-05-01
COMPLETEDIrinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung CancerNCT00003900 · 1999-10-01
COMPLETEDIrinotecan in Treating Patients With Metastatic or Recurrent Breast CancerNCT00004182 · 1999-10-01
COMPLETEDGemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerNCT00004139 · 1999-09-01
COMPLETEDIrinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid TumorsNCT00004095 · 1999-08-01
COMPLETEDPaclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung CancerNCT00004924 · 1999-03-01
COMPLETEDConditions being studied
Lung Cancer22Breast Cancer9Colorectal Cancer4Metastatic Cancer4Metastatic Malignant Solid Neoplasm4Stage III Lung Cancer AJCC v83Stage IV Lung Cancer AJCC v83Advanced Malignant Solid Neoplasm2Extensive Stage Small Cell Lung Cancer2Metastatic Lung Small Cell Carcinoma2Recurrent Breast Cancer2Stage III Pancreatic Cancer AJCC v82Stage IV Breast Cancer2Stage IV Non-small Cell Lung Cancer2Stage IV Pancreatic Cancer AJCC v82Triple-Negative Breast Carcinoma2Unresectable Lung Small Cell Carcinoma2Unresectable Malignant Solid Neoplasm2Unspecified Adult Solid Tumor, Protocol Specific2Advanced Adult Primary Liver Cancer1
Research locations
ChicagoIllinois, United States8St LouisMissouri, United States7BostonMassachusetts, United States6GreenvilleSouth Carolina, United States6OmahaNebraska, United States6BuffaloNew York, United States5CharlestonSouth Carolina, United States5DuluthMinnesota, United States5New HavenConnecticut, United States5PittsburghPennsylvania, United States5RochesterMinnesota, United States5WichitaKansas, United States5
Leading sponsors
Alliance for Clinical Trials in Oncology7National Cancer Institute (NCI)6Northwestern University3Fox Chase Cancer Center2Japan Multinational Trial Organization2Roswell Park Cancer Institute2SWOG Cancer Research Network2University of California, San Francisco2Yale University2Centre Hospitalier Universitaire Vaudois1Federation Francophone de Cancerologie Digestive1M.D. Anderson Cancer Center1Memorial Sloan Kettering Cancer Center1Montefiore Medical Center1National Cancer Institute, France1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.